Severe and Prolonged Thrombocytopenia Following Heparin and Apixaban Use: A Case Report and Literature Review

IF 0.3 Q4 PHARMACOLOGY & PHARMACY
Foroud Shahbazi, M. Salimi
{"title":"Severe and Prolonged Thrombocytopenia Following Heparin and Apixaban Use: A Case Report and Literature Review","authors":"Foroud Shahbazi, M. Salimi","doi":"10.2174/1574885519666230825153414","DOIUrl":null,"url":null,"abstract":"\n\nDrug-induced thrombocytopenia can occur in hospitalized patients and complicate their antithrombotic treatment. Several medications can associate thrombocytopenia with immune and non-immune mechanisms. Thrombocytopenia can occur at any time from a few hours to months after a new medication initiation. In this study, we have described the case of a female patient with acute-on-chronic kidney injury following a non-steroidal anti-inflammatory agent use, who developed catheter-related thrombosis and was treated with heparin without any complication for 5 days. She was discharged after 5 days and prescribed to use apixaban 2.5 mg twice daily. However, she was readmitted after 24 hours with fatigue, petechiae, and severe thrombocytopenia (7000/mm3). The workup was negative for other reasons of thrombocytopenia. With a possible diagnosis of drug-related thrombocytopenia, apixaban was discontinued. Following the treatment with the intravenous immunoglobulin, her platelet counts increased and stabilized around 40-50,000/mm3. Anticoagulation was thus continued with adjusted doses of rivaroxaban (10-15 mg/day). 17 days after apixaban discontinuation and treatment with prednisolone, her platelet count increased to 108,000/mm3. With reference to this case, a brief review on refractory heparin-induced thrombocytopenia and the association of direct oral anticoagulants with thrombocytopenia is presented.\n","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2023-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Drug Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1574885519666230825153414","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Drug-induced thrombocytopenia can occur in hospitalized patients and complicate their antithrombotic treatment. Several medications can associate thrombocytopenia with immune and non-immune mechanisms. Thrombocytopenia can occur at any time from a few hours to months after a new medication initiation. In this study, we have described the case of a female patient with acute-on-chronic kidney injury following a non-steroidal anti-inflammatory agent use, who developed catheter-related thrombosis and was treated with heparin without any complication for 5 days. She was discharged after 5 days and prescribed to use apixaban 2.5 mg twice daily. However, she was readmitted after 24 hours with fatigue, petechiae, and severe thrombocytopenia (7000/mm3). The workup was negative for other reasons of thrombocytopenia. With a possible diagnosis of drug-related thrombocytopenia, apixaban was discontinued. Following the treatment with the intravenous immunoglobulin, her platelet counts increased and stabilized around 40-50,000/mm3. Anticoagulation was thus continued with adjusted doses of rivaroxaban (10-15 mg/day). 17 days after apixaban discontinuation and treatment with prednisolone, her platelet count increased to 108,000/mm3. With reference to this case, a brief review on refractory heparin-induced thrombocytopenia and the association of direct oral anticoagulants with thrombocytopenia is presented.
肝素和阿哌沙班使用后严重和长期的血小板减少:1例报告和文献回顾
药物诱导的血小板减少症可能发生在住院患者中,并使其抗血栓治疗复杂化。几种药物可以将血小板减少症与免疫和非免疫机制联系起来。血小板减少症可在新药开始后数小时至数月内的任何时间发生。在这项研究中,我们描述了一名女性患者在使用非甾体抗炎药后出现急性或慢性肾损伤,出现导管相关血栓形成,并接受肝素治疗5天,没有任何并发症。她在5天后出院,并规定每天两次使用阿哌沙班2.5 mg。然而,她在24小时后因疲劳、瘀点和严重血小板减少症(7000/mm3)再次入院。由于血小板减少症的其他原因,检查结果为阴性。由于可能被诊断为与药物相关的血小板减少症,阿哌沙班被停用。静脉注射免疫球蛋白治疗后,她的血小板计数增加并稳定在40-50000/mm3左右。因此,通过调整剂量的利伐沙班(10-15mg/天)继续抗凝。阿哌沙班停药和泼尼松治疗17天后,她的血小板计数增加到108000/mm3。针对这一病例,简要回顾了难治性肝素诱导的血小板减少症以及直接口服抗凝剂与血小板减少症的关系。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Drug Therapy
Current Drug Therapy PHARMACOLOGY & PHARMACY-
CiteScore
1.30
自引率
0.00%
发文量
50
期刊介绍: Current Drug Therapy publishes frontier reviews of high quality on all the latest advances in drug therapy covering: new and existing drugs, therapies and medical devices. The journal is essential reading for all researchers and clinicians involved in drug therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信